J Rheum Dis.  2015 Jun;22(3):137-139. 10.4078/jrd.2015.22.3.137.

The Effect and Clinical Application of Modified-release Prednisone

• Kim HO
• Lee SI

• KMID: 2222878
• DOI: http://doi.org/10.4078/jrd.2015.22.3.137

Abstract

No abstract available.

MeSH Terms

Prednisone*
Prednisone

Reference

1. Silman AJ, Hochberg MC. Epidemiology of the rheumatic diseases. 2nd ed.New York: Oxford University Press;2001. p. 32–44.

2. World Health Organization. Chronic diseases and health promotion [Internet]. Geneva: World Health Organization;[cited 2014 Jan 1]. Available from:. http://www.who.int/chp/topics/rheumatic/en/.

3. Straub RH, Cutolo M. Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum. 2007; 56:399–408.

4. Perry MG, Kirwan JR, Jessop DS, Hunt LP. Overnight variations in cortisol, interleukin 6, tumour necrosis factor alpha and other cytokines in people with rheumatoid arthritis. Ann Rheum Dis. 2009; 68:63–8.

5. Arvidson NG, Gudbjörnsson B, Larsson A, Hällgren R. The timing of glucocorticoid administration in rheumatoid arthritis. Ann Rheum Dis. 1997; 56:27–31.

6. Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet. 2008; 371:205–14.

7. Cutolo M, Spies CM, Buttgereit F, Paolino S, Pizzorni C. The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis. Arthritis Res Ther. 2014; 16(Suppl 2):S1.

8. Gorter SL, Bijlsma JW, Cutolo M, Gomez-Reino J, Kouloumas M, Smolen JS, et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010; 69:1010–4.

9. Buttgereit F, Mehta D, Kirwan J, Szechinski J, Boers M, Alten RE, et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis. 2013; 72:204–10.

10. Cutolo M, Iaccarino L, Doria A, Govoni M, Sulli A, Marcassa C. Efficacy of the switch to modified-release prednisone in rheumatoid arthritis patients treated with standard glucocorticoids. Clin Exp Rheumatol. 2013; 31:498–505.

11. Boers M, Buttgereit F. A simple model that suggests possible cost savings when modified-release prednisone 5 mg/day is added to current treatment in patients with active rheumatoid arthritis. Rheumatology (Oxford). 2013; 52:1435–7.

12. Alten R, Döring G, Cutolo M, Gromnica-Ihle E, Witte S, Straub R, et al. Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone. J Rheumatol. 2010; 37:2025–31.

13. Yoon KH. Clinical experience with low-dose modi-fied-release prednisone chronotherapy in Asian patients with rheumatoid arthritis in Singapore. J Rheum Dis. 2015; 22:76–84.